Clozapine and cardiomyopathy. An investigation conducted in a Mental Health Service;Clozapina e miocardiopatia. Una ricerca in un Servizio di Salute Mentale

Italian Journal of Psychopathology

Volumn 16, Issue 3, 2010, Pages 286-298

  Domenichetti, S ^a   Rostagno, C ^b   Pastorelli, F ^b   Gensini, G F ^b  

^a UFSMA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Ambulatory care; Cardiomyopathy; Cardiovascular; Clinical pharmacology; Schizophrenia

Indexed keywords

CLOZAPINE;

AGRANULOCYTOSIS; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; HEART LEFT VENTRICLE FAILURE; HUMAN; LEUKOPENIA; MENTAL HEALTH SERVICE; MYOCARDITIS; PERICARDITIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUDDEN DEATH;

EID: 78650322811     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Kety SS, Ingraham LJ. Genetic transmission and improved diagnosis of schizophrenia in pedigrees of adoptees. J Psychiatr Res 1992; 26:247-55.
2. Kendell RE, Brockington IF. The identification of disease entities and the relationship between schizophrenic and affective psychoses. Br J Psychiatry 1980;137:324-31.
3. Janzarik W. Dynamische grundkonstellationen in endogenen psychosen. Berlin: Springer 1959.
4. Huber G. Das Konzept substratnaher basissymptome und seine bedeutung für theorie und therapie schizophrener erkrankungen. Nervenarzt 1983;54:23-32.
5. Lenz G, Simhandl C, Thau K, et al. Temporal stability of diagnostic criteria for functional psychoses. Results from the Vienna follow-up study. Psychopathology 1991;24:328-35.
6. Maj M. Critique of DSM-IV operational diagnostic criteria for schizophrenia. Br J Psychiatry 1998;172:459-60.
7. Andreasen NC. Schizofrenia. Torino: Centro Scientifico Editore 1998.
8. Cutting J. Psicologia della schizofrenia. Torino: Bollati Boringhieri 1989.
9. Ciompi L. Schizophrenic deterioration. Br J Psychiatry 1983;143:79-80.
10. Tognoni G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. Eur J Clin Pharmacol 1999;5:685-90.
11. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9.
12. Goya Wannamethee S, Shaker AG, et al. Adult height, stroke, and coronary heart disease. Am J Epidemiol 2005;148:1069-76.
13. Agenzia Italiana del Farmaco, Determinazione del 28.2.2007.
14. Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9:410-8.
15. Trollor JN, Valenzuela MJ. Brain ageing in the new millennium. Aust N Z J Psychiatry 2001;35:788-805.
16. Zahoronda A, Bobula B, Tokarski K, et al. The influence of repeated administration of clozapine and haloperidol on the effects of the activation of 5-HT1A, 5-HT2 and 5-HT4 receptors in rat frontal cortex. J Physiol Pharmacol 2004;55:371-9. (Pubitemid 38901969)
17. Güzelcan Y, Scholte WF. Door clozapine geïnduceerde agranulocytose: genetische en immunologische verklaringen. Tijdschr Psychiatr 2006;48:295-302.
18. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
19. Vesterby A, Pedersen JH, Kaempe B, et al. Sudden death during treatment with clozapine (Leponex). Ugeskr Laeger 1980;142:170-1. (Pubitemid 10183941)
20. Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
21. Vesterby A, Pedersen JH, Kaempe B, et al. Sudden death during treatment with clozapine. Ugeskr Laeger 1980;142:170-1.
22. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
23. Novartis Pharma Canada. Association of clozapine and cardiovascular toxicity - 2002.
24. Hägg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21:382-8.
25. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005;25:32-41.
26. Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004;38:915-22. (Pubitemid 40028895)
27. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57.
28. Wooltorton E. Antipsychotic clozapine (clozaril): myocarditis and cardiovascular toxicity. CMAJ 2002;166:1185-6.
29. Cohen H, Loewenthal U, Matar M, et al. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 2001;179:167-71.
30. Whynne J, Braunwald E. The cardiomyopathy and myocarditis. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia: W.B. Saunder 2001, pp. 1751-806.
31. Rostagno C, Di Norscia G, Placidi GF, et al. Beta-blocker and angiotensinconverting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. Gen Hosp Psychiatry 2008;30:280-3. (Pubitemid 351538957)